investorscraft@gmail.com

Intrinsic value of OraSure Technologies, Inc. (OSUR)

Previous Close$3.17
Intrinsic Value
Upside potential
Previous Close
$3.17

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh11.39 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, and OraSure QuickFlu Rapid Flu A&B test; OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; tuberculosis products; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %36.1NaN
Revenue, $234NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m244NaN
Operating income, $m-10NaN
EBITDA, $m1NaN
Interest expense (income), $mNaN
Earnings before tax, $m-9NaN
Tax expense, $m14NaN
Net income, $m-23NaN

BALANCE SHEET

Cash and short-term investments, $m153NaN
Total assets, $m461NaN
Adjusted assets (=assets-cash), $m308NaN
Average production assets, $m133NaN
Working capital, $m220NaN
Total debt, $m12NaN
Total liabilities, $m80NaN
Total equity, $m381NaN
Debt-to-equity ratio0.032NaN
Adjusted equity ratio0.749NaN

CASH FLOW

Net income, $m-23NaN
Depreciation, amort., depletion, $m12NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-35NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-48NaN
Free cash flow, $m13NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m220
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount